BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 117 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
| Q2 2020 | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
| Q1 2020 | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
| Q4 2019 | $9,746,000 | +4677.5% | 2,825,000 | +11200.0% | 2.41% | +2388.7% |
| Q1 2019 | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% |
| Q4 2018 | $202,000 | -95.4% | 25,000 | -97.2% | 0.15% | -81.5% |
| Q4 2017 | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
| Q3 2017 | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
| Q2 2017 | $938,000 | -91.0% | 168,685 | -86.5% | 0.26% | -89.4% |
| Q1 2017 | $10,461,000 | +563.3% | 1,245,310 | +400.1% | 2.48% | +323.2% |
| Q4 2016 | $1,577,000 | -49.8% | 249,000 | -65.0% | 0.59% | -50.3% |
| Q3 2016 | $3,141,000 | +1.5% | 712,248 | +162.4% | 1.18% | -34.1% |
| Q3 2015 | $3,094,000 | – | 271,399 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |